Today’s Phase IIb trial results investigating nebulized ensifentrine as a twice-daily add-on to a long-acting antimuscarinic bronchodilator (LAMA) in symptomatic patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) are excellent and highly supportive of the overall drug’s profile. In the study, ensifentrine met its primary endpoint (peak FEV1 at week 4) for all doses, showing a dose-responsive statistically significant and clinically meaningful improvement of lung functi ....
13 Jan 2020
Excellent final Phase IIb data sets an impressive marker
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Excellent final Phase IIb data sets an impressive marker
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
13 Jan 2020 -
Author:
Edward Thomason -
Pages:
4
Today’s Phase IIb trial results investigating nebulized ensifentrine as a twice-daily add-on to a long-acting antimuscarinic bronchodilator (LAMA) in symptomatic patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) are excellent and highly supportive of the overall drug’s profile. In the study, ensifentrine met its primary endpoint (peak FEV1 at week 4) for all doses, showing a dose-responsive statistically significant and clinically meaningful improvement of lung functi ....